Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
12:39:32 EDT Sat 06 Jun 2026
Enter Symbol
or Name
USA
CA



Forgot password?
Trouble logging in?
Login ID:
Password:
Save

News for U:RARE from 2025-06-06 to 2026-06-05 - 46 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2026-06-03 16:30U:RARENews ReleaseUltragenyx to Participate at Goldman Sachs 47th Annual Global Healthcare Conference
2026-05-22 16:30U:RARENews ReleaseUltragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2026-05-06 16:30U:RARENews ReleaseUltragenyx to Participate at Bank of America's 2026 Healthcare Conference
2026-05-05 16:01U:RARENews ReleaseUltragenyx Reports First Quarter 2026 Financial Results and Corporate Update
2026-04-29 08:00U:RARENews ReleaseUltragenyx to Host Conference Call for First Quarter 2026 Financial Results and Corporate Update
2026-04-24 16:30U:RARENews ReleaseUltragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2026-04-02 08:30U:RARENews ReleaseUltragenyx Announces U.S. FDA Acceptance of BLA Resubmission for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA)
2026-03-30 08:30U:RARENews ReleaseUltragenyx Announces FDA Clearance of Investigational New Drug (IND) Application for UX016, a Sialic Acid Prodrug for the Treatment of GNE Myopathy
2026-03-20 16:30U:RARENews ReleaseUltragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2026-03-13 22:16U:RARENews ReleaseUltragenyx Pharmaceutical Inc. Notice of April 6, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
2026-03-12 08:30U:RARENews ReleaseUltragenyx Announces Positive 36-Week Data from Phase 3 Study of DTX301 AAV8 Gene Therapy for the Treatment of Ornithine Transcarbamylase (OTC) Deficiency
2026-02-23 16:30U:RARENews ReleaseUltragenyx to Participate at Investor Conferences in March
2026-02-23 08:30U:RARENews ReleaseUltragenyx Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application (BLA) for DTX401 AAV Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)
2026-02-20 16:30U:RARENews ReleaseUltragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2026-02-12 16:01U:RARENews ReleaseUltragenyx Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate Update
2026-02-05 16:05U:RARENews ReleaseUltragenyx to Host Conference Call for Fourth Quarter and Full-Year 2025 Financial Results and Corporate Update
2026-02-03 08:00U:RARENews ReleaseUltragenyx Announces Positive Longer-Term Data Demonstrating Treatment with UX111 Gene Therapy Results in Sustained, Significant Reductions in CSF-HS and Continued Meaningful Improvements in Clinical Function Across Multiple Developmental Domains in Child
2026-01-30 08:30U:RARENews ReleaseUltragenyx Resubmits Biologics License Application for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA) to U.S. FDA
2026-01-23 16:30U:RARENews ReleaseUltragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2026-01-12 07:30U:RARENews ReleaseUltragenyx Provides Financial and Business Updates at J.P. Morgan Annual Healthcare Conference
2026-01-07 16:05U:RARENews ReleaseUltragenyx to Present at the 44th Annual J.P. Morgan Healthcare Conference
2025-12-30 16:05U:RARENews ReleaseUltragenyx Completes Rolling Submission of Biologics License Application (BLA) to U.S. FDA for DTX401 AAV Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)
2025-12-29 08:30U:RARENews ReleaseUltragenyx Announces Phase 3 Orbit and Cosmic Results for Setrusumab (UX143) in Osteogenesis Imperfecta
2025-12-19 16:30U:RARENews ReleaseUltragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2025-11-24 16:30U:RARENews ReleaseUltragenyx to Participate in Investor Conferences in December
2025-11-21 16:30U:RARENews ReleaseUltragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2025-11-04 16:05U:RARENews ReleaseUltragenyx Reports Third Quarter 2025 Financial Results and Corporate Update
2025-11-04 16:01U:RARENews ReleaseUltragenyx Announces Sale of a Portion of Future North American Royalties on Crysvita(TM) (burosumab) for $400 Million to OMERS Life Sciences
2025-10-30 08:00U:RARENews ReleaseUltragenyx Announces First Patient Dosed in Aurora Study Evaluating GTX-102 in Additional Angelman Syndrome Genotypes and Age Groups
2025-10-28 16:30U:RARENews ReleaseUltragenyx to Host Conference Call for Third Quarter 2025 Financial Results and Corporate Update
2025-10-24 16:30U:RARENews ReleaseUltragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2025-10-03 16:30U:RARENews ReleaseUltragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2025-09-30 16:05U:RARENews ReleaseUltragenyx Appoints Eric Olson as Chief Business Officer and Executive Vice President
2025-09-19 16:30U:RARENews ReleaseUltragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2025-09-08 16:05U:RARENews ReleaseUltragenyx Announces Positive Longer-term Data from Phase 3 Study of DTX401 AAV Gene Therapy for the Treatment of Glycogen Storage Disease Type Ia (GSDIa)
2025-08-29 16:30U:RARENews ReleaseUltragenyx to Participate at Investor Conferences in September
2025-08-21 17:00U:RARENews ReleaseUltragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2025-08-18 08:00U:RARENews ReleaseUltragenyx Initiates Rolling Submission of Biologics License Application (BLA) to U.S. FDA for DTX401 AAV Gene Therapy for the Treatment of Glycogen Storage Disease Type Ia (GSDIa)
2025-07-31 16:05U:RARENews ReleaseUltragenyx Completes Enrollment of Phase 3 Aspire Study Evaluating GTX-102 for the Treatment of Angelman Syndrome
2025-07-30 08:30U:RARENews ReleaseUltragenyx to Host Conference Call for Second Quarter 2025 Financial Results and Corporate Update
2025-07-18 16:30U:RARENews ReleaseUltragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2025-07-14 08:00U:RARENews ReleaseHealth Canada Extends the Approval of Evkeeza(TM) (evinacumab) to Children as Young as 6-months Old with Homozygous Familial Hypercholesterolemia (HoFH)
2025-07-11 16:30U:RARENews ReleaseUltragenyx Receives Complete Response Letter from FDA for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA)
2025-07-09 16:05U:RARENews ReleaseUltragenyx and Mereo BioPharma Announce UX143 Phase 3 Orbit Study for Osteogenesis Imperfecta Progressing to Final Analysis
2025-06-27 08:00U:RARENews ReleaseUltragenyx Receives Breakthrough Therapy Designation for GTX-102 in Angelman Syndrome
2025-06-20 16:30U:RARENews ReleaseUltragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)